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Abstract: Cardiovascular disease is the leading cause of morbidity/mortality worldwide. Metformin
is the first therapy offering cardioprotection in type 2 diabetes and non-diabetic animals with
unknown mechanism. We have shown that metformin improves angiogenesis via affecting expression
of growth factors/angiogenic inhibitors in CD34+ cells under hyperglycemia-hypoxia. Now we
studied the direct effect of physiological dose of metformin on human umbilical vein endothelial cells
(HUVEC) under conditions mimicking hypoxia-hyperglycemia. HUVEC migration and apoptosis
were studied after induction with euglycemia or hyperglycemia and/or CoCl2 induced hypoxia in
the presence or absence of metformin. HUVEC mRNA was assayed by whole transcript microarrays.
Genes were confirmed by qRT-PCR, proteins by western blot, ELISA or flow cytometry. Metformin
promoted HUVEC migration and inhibited apoptosis via upregulation of vascular endothelial growth
factor (VEGF) receptors (VEGFR1/R2), fatty acid binding protein 4 (FABP4), ERK/mitogen-activated
protein kinase signaling, chemokine ligand 8, lymphocyte antigen 96, Rho kinase 1 (ROCK1), matrix
metalloproteinase 16 (MMP16) and tissue factor inhibitor-2 under hyperglycemia-chemical hypoxia.
Therefore, metformin’s dual effect in hyperglycemia-chemical hypoxia is mediated by direct effect
on VEGFR1/R2 leading to activation of cell migration through MMP16 and ROCK1 upregulation,
and inhibition of apoptosis by increase in phospho-ERK1/2 and FABP4, components of VEGF
signaling cascades.
Keywords: cardiovascular disease; ischemia; diabetes; VEGF signaling
1. Introduction
Cardiovascular disease (CVD) remains the leading cause of death worldwide according to the
World Health Organization 2016 mortality database. The outcome of CVD management is affected by
diabetes mellitus (DM), which results in a two- to four-fold increased risk of CVD [1,2]. The outcomes
of CVD interventions such as percutaneous coronary intervention (PCI) and coronary artery bypass
graft are much worse in diabetic than non-diabetic individuals [3,4].
Diabetes associated endothelial dysfunction is a known early step in the adverse sequence of
events leading to the development of micro- and macrovascular complications, which results in
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mortality linked to diabetes in 75% of cases [5]. Vascular complications include both qualitative
and quantitative changes in vascular architecture, in particular: abrogation of neovascularization
and remodeling of the existing vasculature that results in a lack of ability to control ischemic injury.
Understanding the mechanisms involved in diabetes associated impaired vascular repair and known
interventions is paramount. Therefore, investigating drugs affecting angiogenesis during a therapeutic
window for myocardial infarction (1 h), delayed (3 h) and prolonged (12 h) period of ischemia
and acute hyperglycemia is of importance. Metformin is the first hypoglycemic therapy to display
cardioprotective properties as shown in long-term randomized clinical trials [6,7]. Furthermore, when
used in patients with metabolic syndrome, post-PCI myocardial injury was improved [8].
Pre-treatment of diabetic patients with metformin was found to be associated with reduced
myocardial infarction (MI) size compared to non-metformin treated [9]. Additionally, studies in animal
models suggested that metformin at physiological doses improved coronary blood flow following
MI [10], and limited infarct size in diabetic rats [11]. Our recent work has shown that metformin
improved angiogenesis by augmenting the expression of VEGFA and reducing angiogenic inhibitors in
CD34+ cells under hyperglycemia-hypoxia [12]. However, no data on the direct effect of physiological
doses of metformin on vascular repair (migration, apoptosis) under hyperglycemia-hypoxia is available
to date.
In this paper, we hypothesized that metformin at physiological dose enhances endothelial cell
(EC) survival and migration under the conditions of hyperglycemia and hypoxia. As it is important for
the research to be of translational value, we specifically applied clinically relevant physiological doses
of metformin. Although cell culture systems have certain limitations in mimicking and simulating
CVD; they are indispensable tools to unravel critical underlying molecular mechanisms of the disease.
Therefore, we employed freshly isolated HUVEC from different donors as an in vitro model to study
the effect of physiological concentration of metformin on cell survival, migration and gene expression
under chemical hypoxia and hyperglycemia.
2. Results
2.1. Metformin Promotes Endothelial Cell Migration under Hyperglycemia-CoCl2
Metformin reduced cell migration under euglycemia-CoCl2 at 18 (p < 0.01) and 24 h (p < 0.001,
Figure 1B) of CoCl2 but accelerated cell migration under hyperglycemia-CoCl2 at 24 h of CoCl2
(p < 0.01, Figure 2C).
Euglycemia-CoCl2 had no effect on EC migration compared to control (Figure 1A,B). However,
hyperglycemia alone significantly increased migration at 6 (p < 0.001), 12 (p < 0.001), and 18 h (p < 0.001,
Figure 2A,B) but not at 24 h (plateau phase). Hyperglycemia-CoCl2 inhibited migration at 6 (p < 0.001),
12 (p < 0.001), 18 (p < 0.001), and 24 h of CoCl2 (p < 0.01, Figure 2A,C) compared to hyperglycemia alone.
2.2. Inhibition of Metformin Action Mediated by VEGFA in Cell Migration Assay
Sunitinib, a VEGF inhibitor, blocked the effect of metformin in euglycaemia-CoCl2 and
hyperglycemia-CoCl2 (Figure 1A,B and Figure 2A,C).
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Figure 1. Metformin impairs cell migration in HUVEC exposed to euglycemia and CoCl2. (A) HUVEC 
were incubated for 24 h with euglycemia in the presence or absence of metformin. Scratch lines were 
created on confluent monolayers. The media containing different glucose concentrations and 
metformin were replaced. Then cells were incubated with CoCl2 for 24 h in a 5% CO2 chamber that 
was connected to CCD camera. Images were acquired every hour, and three independent biological 
experiments were performed at which each condition was assessed in duplicate. The scratch area was 
measured using NIS Elements software. (B) CoCl2 induction exhibited no significant effect on cell 
migration under euglycemia, whereas metformin reduced migration after 18 h. Sunitinib (0.1 µmol/L) 
was used as a negative control, therefore the line with sunitinab is on x axis as cell migration not 
affected. Results are expressed as mean ± SEM and were analyzed by one-way ANOVA followed by 
LSD, ## p < 0.01, ### p < 0.001 compared pairwise, i.e., the metformin-treated versus metformin-
untreated condition. Scale bar is 100 µm. Key: met: metformin; sun: sunitinib. 
 
Figure 2. Metformin improves cell migration in HUVEC exposed to hyperglycemia and CoCl2. (A) 
HUVEC were incubated for 24 h with hyperglycemia in the presence or absence of metformin. Scratch 
lines were created on confluent monolayers. The media containing different glucose concentrations 
and metformin were replaced. Then cells were incubated with CoCl2 for 24 h in a 5% CO2 chamber 
that was connected to CCD camera. Images were acquired every hour, and three independent 
biological experiments were performed at which each condition was assessed in duplicate. The 
scratch area was measured using NIS Elements software. (B) Hyperglycemia increased migration 
after 6, 12, and 18 h; (C) whereas hyperglycemia-CoCl2 significantly reduced migration. Metformin 
increased cell migration under hyperglycemia-CoCl2. Sunitinib was used as a negative control, 
therefore the line with sunitinab is on x axis as cell migration not affected. Results are expressed as 
mean ± SEM and were analyzed by one-way ANOVA followed by LSD, ** p < 0.01, *** p < 0.001 
compared to the control. ## p < 0.01, ### p < 0.001 compared pairwise, i.e., the metformin-treated versus 
metformin-untreated condition. Scale bar is 100 µm. Key: met: metformin; sun: sunitinib. 
Figure 1. Metformin impairs cell migration in HUVEC exposed to euglycemia and CoCl2. (A) HUVEC
were incubated for 24 h with euglycemia in the presence or absence of metformin. Scratch lines were
created on confluent monolayers. The media containing different glucose concentrations and metformin
were replaced. Then cells were incubated with CoCl2 for 24 h in a 5% CO2 chamber that was connected
to CCD ca ra. Images were acquired every hour, a d three independent biological experiments were
performed at which each condition s assessed in dupl cat . The scratch area was measured using
NIS Elements software. (B) CoCl2 inducti n exhibited no significant effect o cell migration under
euglycemia, whereas metformin reduced migration after 18 h. Sunitinib (0.1 µmol/L) was used as a
negative control, therefore the line with sunitinab is on x axis as cell migration not affected. Results
are expressed as mean ± SEM and were analyzed by one-way ANOVA followed by LSD, ## p < 0.01,
### p < 0.001 compared pairwise, i.e., the metformin-treated versus metformin-untreated condition.
Scale bar is 100 µm. Key: met: metformin; sun: sunitinib.
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Figure 2. Metformin improves cell migration in HUVEC exposed to hyperglycemia and CoCl2.
(A) HUVEC were incubated for 24 h with hyperglycemia in the presence or absence of metformin.
Scratch lines were created on confluent monolayers. The media containing different glucose
concentrations and metformin were replaced. Then cells were incubated with CoCl2 for 24 h in
a 5% CO2 chamber that was connected to CCD camera. Images were acquired every hour, and
three independent biological experiments were performed at which ea h condition was assessed in
duplicat . The scratch area was measured using NIS Elements softwar . (B) Hype glycemia increased
migration after 6, 12, and 18 h; (C) whereas hyperglycemia-CoCl2 significantly reduced migration.
Metfor in increased cell migration under hyperglycemia-CoCl2. Sunitinib was used as a negative
control, therefore the line with sunitinab is on x axis as cell migration not affected. Results are expressed
as mean ± SEM and were analyzed by one-way ANOVA followed by LSD, ** p < 0.01, *** p < 0.001
compared to the control. ## p < 0.01, ### p < 0.001 compared pairwise, i.e., the metformin-treated versus
metformin-untreated condition. Scale bar is 100 µm. Key: met: metformin; sun: sunitinib.
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2.3. Metformin Reduces Apoptosis under Hyperglycemia-CoCl2
Metformin significantly reduced the apoptosis (−1.3-fold, p = 0.045) under hyperglycemia-CoCl2
at 24 h of CoCl2 (Figure 3D). However, metformin concentration exhibited no effect on HUVEC
apoptosis under euglycemia-CoCl2 at 3, 12, or 24 h of CoCl2 or under hyperglycemia-CoCl2 at 3
and 12 h of CoCl2 (Figure S1). A supra-physiological concentration of metformin (1.0 mmol/L)
non-significantly enhanced apoptosis (1.3-fold, p > 0.05) in HUVEC treated with hyperglycemia for
48 h (Figure 3C).
No effect on apoptosis at 3 and 12 h of CoCl2 was detected neither under euglycemia nor
hyperglycemia (Figure 3A,B). At 24 h of CoCl2 there was a non-significant increase (1.3-fold, p > 0.05)
in the apoptotic cells under euglycemic conditions (Figure 3A); but a significant increase (1.9-fold,
p = 0.018) under hyperglycemia-CoCl2 (Figure 3B).
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Figure 3. Metformin improves cell survival with hyperglycemia-CoCl2. (A) HUVEC were treated with 
5.5 or (B) 16.5 mmol/L glucose for 48 h exposed to chemical hypoxia for 3, 12 or 24 h in the absence of 
metformin, (C) hyperglycemia treated with metformin (0.01 mmol/L) and supra-physiological 
concentration of metformin (1.0 mmol/L), and (D) hyperglycemia exposed to CoCl2 for 24 h and 
parallel cultures were treated with metformin. Apoptosis was assessed by Annexin V staining and 
flow cytometry. Results are representative of 3 independent experiments and expressed as mean ± 
SEM and were analyzed by paired t-test, * p < 0.05, compared to hyperglycemia, # p < 0.05 compared 
pairwise, i.e., metformin-treated condition versus untreated condition. 
2.4. Microarray Gene Expression Profiling in HUVEC and Western Blot 
In the microarray experiments, the number of differentially expressed genes with a p-value < 
0.05 and a cutoff fold change of 1.5 varied considerably between the conditions. 
2.5. Metformin Has No Effect on HIF-1α Gene/Protein Expression under Hyperglycemia-CoCl2 
Transcriptome analysis demonstrated that physiological concentration of metformin exerted no 
effect on HIF-1α signaling when HUVEC were exposed to CoCl2 for 1, 3, 12 h either under euglycemia 
or hyperglycemia. Western blot (WB) assay revealed that metformin led to a significant 
downregulation of HIF-1α protein levels at 1 h of CoCl2 under euglycemia-CoCl2 (−7.6-fold, p < 0.001) 
but exhibited no effect under hyperglycemia-CoCl2 (Figure S2). 
Figure 3. Metformin improves cell survival with hyperglycemia-CoCl2. (A) HUVEC were treated with
5.5 or (B) 16.5 mmol/L glucose for 48 h exposed to chemical hypoxia for 3, 12 or 24 h in the absence
of metformin, (C) hyperglycemia treated with metformin (0.01 mmol/L) and supra-physiological
concentration of metformin (1.0 mmol/L), and (D) hyperglycemia exposed to CoCl2 for 24 h and
parallel cultures were treated with metformin. Apoptosis was assessed by Annexin V staining and flow
cytometry. Results are representative of 3 independent experiments and expressed as mean ± SEM and
were analyzed by paired t-test, * p < 0.05, compared to hyperglycemia, # p < 0.05 compared pairwise,
i.e., metformin-treated condition versus untreated condition.
2.4. Microarray Gene Expression Profiling in HUVEC and Western Blot
In the micr array experiments, the number of differentially expressed genes with a p-value < 0.05
and a cutoff fold change of 1.5 varied considerably between the conditions.
2.5. Metformin Has No Effect on HIF-1α Gene/Protein Expression under Hyperglycemia-CoCl2
Transcriptome a lysis demonstrated that physiological concentration of metformin exerted no
effect on HIF-1α signaling when HUVEC were exposed to CoCl2 for 1, 3, 12 h either under euglycemia
or hyperglycemia. Western blot (WB) assay revealed that metformin led to a significant downregulation
of HIF-1α protein lev ls at 1 h of CoCl2 under euglycemia-CoCl2 (−7.6-fold, p < 0.001) but exhibited
no effect under hyperglycemia-CoCl2 (Figure S2).
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HIF-1α mRNA levels at 1 and 3 h of CoCl2 were unchanged under euglycemia-CoCl2 and
hyperglycemia-CoCl2. Whereas, a significant decrease was detected at 12 h of CoCl2 in both euglycemia
(−1.6-fold, p = 1.4 ×10−6) and hyperglycemia (−1.9-fold, p = 4.4 × 10−9). WB revealed a significant
increase in HIF-1α protein at 1 h of CoCl2 under euglycemia-CoCl2 (3.4-fold, p < 0.01) but no significant
increase under hyperglycemia-CoCl2 (Figure S2).
2.6. Metformin Has No Significant Effect on VEGFA Gene Expression but Increased Protein Expression at 1 h
of CoCl2 under Hyperglycemia-CoCl2
Metformin exhibited no effect on VEGFA mRNA expression under euglycemia-CoCl2 and
hyperglycemia-CoCl2 up to 12 h as assayed by microarray and qRT-PCR (Figure 4A) versus parallel
condition without metformin.
In WB, metformin exhibited no significant effect on VEGF 165A protein expression under
euglycemia-CoCl2. However, under hyperglycemia-CoCl2, metformin significantly increased VEGF
165A protein level at 1 h of CoCl2 (7.7-fold, p = 0.012), whereas the level decreased at 12 h of CoCl2
(−5.2-fold, p = 0.019) versus parallel conditions without metformin (Figure 4B).
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Figure 4. Effect of metformin on VEGFA mRNA and VEGF 165A protein under euglycemia-CoCl2,
hyperglycemia and hyperglycemia-CoCl2. HUVEC were treated with hyperglycemic or euglycemic
glucose concentrations as a control. After 24 h, metformin was added to euglycemic and hyperglycemic
cultures, then CoCl2 was added for either 1, 3 or 12 h. (A) The variation in mRNA expression levels of
VEGFA was assessed by qRT-PCR on three independent biological replicates and (B) the variation in
protein levels of VEGF 165A was assessed by western blot on three indepe dent biological replicates.
Results are present d as mean ± SEM and were analyzed using on -w y ANOVA f llowed by LSD,
* p < 0.05, ** p < 0.01 compared to the control. # p < 0.05 compared pairwise, i.e.; metformin-treated
condition versus untreated condition.
Int. J. Mol. Sci. 2018, 19, 293 6 of 18
Transcriptome analysis showed a time dependent increase in VEGFA mRNA upon exposure
to CoCl2 (1, 3, or 12 h) under euglycemia (1.8-fold, 3.79-fold, and 5.15-fold respectively) and
hyperglycemia (1.6-fold, 3.5-fold, 4.7-fold respectively). qRT-PCR validation showed upregulation of
VEGFA upon exposure to CoCl2 at 3 and 12 h under euglycemia-CoCl2 (7.2-fold, p = 0.017 and 9.4-fold,
p = 0.002 respectively versus no CoCl2), and hyperglycemia-CoCl2 (7.4-fold, p = 0.015 and 8.4-fold,
p = 0.005 respectively versus hyperglycemia alone) as illustrated in Figure 4A.
In WB VEGF 165A protein expression was unchanged under euglycemia-CoCl2 but was
significantly upregulated at 12 h of CoCl2 under hyperglycemia-CoCl2 (6.8-fold, p = 0.011 compared to
hyperglycemia alone) but not at 1 or 3 h (Figure 4B).
2.7. Metformin Activates VEGF Downstream Signaling
Several key signaling cascades, including ERK/MAPK and PI3K/Akt pathways are known to
be implicated in the modulation of VEGF induced angiogenic and proliferation effects mediated via
VEGFR1 [13]. Microarray studies showed that the mRNA of VEGFR1 (alias FLT1) was upregulated
(1.7-fold, p = 7.36× 10−3) under euglycemia-CoCl2 at 12 h of CoCl2 but not under hyperglycemia-CoCl2.
A number of VEGFR1 downstream genes was significantly differentially expressed under euglycemia
and hyperglycemia following 12 h of CoCl2 exposure. Among these genes was the mitogen-activated
protein kinase kinase 1 (MAP2K1), a key molecule in the ERK1/2 MAP kinase pathway, with 1.7-fold
(p = 5.37 × 10−9) upregulated under euglycemia-CoCl2, and 1.6-fold (p = 6.8 × 10−8) upregulated
under hyperglycemia-CoCl2. Moreover, gene expression of phosphoinositide-3-kinase, regulatory
subunit 1 (PI3KR1) which is a PI3K/Akt signaling molecule, was increased at 12 h CoCl2 with
euglycemia to 1.9-fold (p = 2.25 × 10−7) and hyperglycemia to 1.7-fold (p = 7.37 × 10−6). In contrast,
PI3KR3 was detected to be downregulated by −2.5-fold (p = 2.09 × 10−9) under euglycemia-CoCl2 at
12 h of CoCl2.
To substantiate these findings, the protein levels of VEGFR1 and VEGFR2 were assessed by ELISA.
Metformin increased the expression of VEGFR1 and VEGFR2 only under hyperglycemia-CoCl2 at 3 h
of CoCl2 (1.5-fold, p = 0.02 and 1.4-fold, p = 0.02 respectively (Figures S4 and S5)).
The expression of VEGFR1 was upregulated under hyperglycemia-CoCl2 at 1, 3, 12 h of CoCl2
exposure (1.8-fold, p = 0.02; 1.6-fold, p = 0.04; 1.9-fold, p = 0.01) compared to hyperglycemia alone
(Figure S3a). Whereas, the expression of VEGFR2 showed downregulation under euglycemia-CoCl2 at
1, 3, 12 h of CoCl2 (−1.3-fold, p = 0.034; −1.3-fold, p = 0.04; −1.9-fold, p < 0.001) and hyperglycemia
(−1.4-fold, p = 0.015) compared to euglycemia. However, hyperglycemia-CoCl2 led to decrease in
VEGFR2 at 12 h of CoCl2 (−1.4-fold, p = 0.034) compared to hyperglycemia (Figure S3b).
2.7.1. MAPK Pathway; Metformin Increases Phosphor-ERK1/2 to Total ERK Ratio
under Hyperglycemia-CoCl2
Metformin led to significant decrease of phospho-ERK1/2 to total ERK ratio to 32.5% (p = 0.007)
under euglycemia-normoxia (Figure 5B). Whereas an increase of phopho-ERK1/2 to total ERK ratio by
33.6% (p = 0.024) was observed under hyperglycemia-CoCl2 at 12 h of CoCl2 (Figure 5C). No change
in the activity of ERK1/2 was detected under euglycemia-CoCl2 or hyperglycemia-normoxia when
compared pairwise.
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Figure 5. Effect o metfor in on the activity of MAPK pathway. HUVEC were treated with euglycemia
or hyperglycemia in th presence or absenc of metformin for 48 h, a d parallel cultures were exposed
to CoCl2 for 12 h. (A) Represents % of ERK1/2 phosphorylation (B) Effect of metformin on euglycemia,
and (C) hyperglycemia combined with 12 h chemical hypoxia CoCl2. Percentage of phosphorylation
indicates relative intensity of phospho-protein/total protein. The variation in protein expression levels
was assessed by flow cytometry on three independent biological replicates. Results are presented as
mean ± SEM and were analyzed using paired t-test. * p < 0.05, ** p < 0.01, *** p < 0.002 compared
to the control. # p < 0.05, ## p < 0.01 compared pairwise, i.e., metformin-treated condition versus
untreated condition.
We observed a significant decrease in phosphorylation ratio of ERK1/2 to 12.0% (p = 0.004) at 12 h
of CoCl2 under euglycemia, to 33.8% (p = 0.05) under hyperglycemia al ne, nd to 7.5% (p = 0.001)
at 12 h of CoCl2 under hyperglycemia- oCl2 (Figure 5A). Whereas, no significant change in the
expression of total ERK1/2 protein was detected in all conditions assayed.
2.7.2. Metformin Increases the Expression of CXCL8, LY96, ROCK1, MMP16, TFPI2, and FABP4
under Hyperglycemia-CoCl2
Microarray data showed that metformin, under hyperglycemia-CoCl2 at 12 h of CoCl2,
significantly upregulated chemokine (C-X-C Motif) ligand 8 (CXCL8) to 1.9-fold (p = 2.84 × 10−2),
lymphocyte antigen 96 (LY96) to 1.6-fold (p = 2.01 × 10−3), MMP16 to 1.7-fold (p = 2.34 × 10−2),
and Rho-associ ted, coiled-coil containing protein kinase 1 (ROCK1) to 2.7-fold (p = 1.15 × 10−2) that
are known to enhance cell migration. Furthermore, metformin le to a significant verexpression of
tissue factor pathway inhibitor 2 (TFPI2), a regulator of EC migration [6], to 1.6-fold (p = 2.07 × 10−4)
under hyperglycemia-CoCl2 at 12 h of CoCl2.Whilst, this effect was not observed without metformin
leading to downregulation of LY96 to−1.7-fold (p = 5.4× 10−4), and TFPI2 to−1.7-fold (p = 1.4 × 10−5).
The most differentially expressed genes affected by metformin under hyperglycemia-CoCl2 are
summarized in Table 1.
Fatty acid binding protein 4 (FABP4) mRNA levels were downregulated at 12 h of CoCl2 in
euglycemia (−1.6-fold, p = 2.4 × 10−2) and hyperglycemia (−1.6-fold, p = 2.9 × 10−2). Conversely,
the expression of FABP4 was significantly induced by adding metformin to HUVEC cultured under
hyperglycemia-CoCl2 at 12 h of CoCl2 (1.6-fold, p = 2.53 × 10−2).
MMP16 was selected to be validated by qRT-PCR showing that hyperglycemia increased the
mRNA level (1.4-fold, p = 0.023) compared to control. There was a decrease in MMP16 expression
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under hyperglycemia-CoCl2 at 12 h of CoCl2 (−1.9-fold, p < 0.001) compared to hyperglycemia alone
(Figure 6). However, metformin significantly increased the mRNA level of MMP16 by 1.5-fold, p = 0.04
under hyperglycemia-CoCl2 at 12 h of CoCl2 versus parallel conditions without metformin.Int. J. Mol. Sci. 2018, 19, 293 8 of 18 
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Table 1. The top differentially expressed genes in HUVEC treated with metformin and exposed to
hyperglyemia-CoCl2.
Gene Name Gene Symbol p-Value
FC
Hyperglycemia-CoCl2
3 h + Metformin
p-Value
FC
Hyperglycemia-CoCl2
12 h + Metformin
small nucleolar RNA,
H/ACA box 20 SNORA20 5.45 × 10
−1 − 28 1.23 × 10−3 4.01
small nucleolar RNA, C/D
box 45C SNORD45C 3.62 × 10
−1 −1.50 1.26 × 10−2 3.16
metastasis associated lung
adenocarcin m transcript 1
(non-protein)
MALAT1 2.88 × 10−2 2.38 8.78 × 10−3 2.87
Rho-associated, coiled-coil
containing protein kinase 1 ROCK1 9.38 × 10
−2 1.90 1.15 × 10−2 2.68
cerebellar
degeneration-related protein
1, 34 kDa
CDR1 5.47 × 10−3 2.80 1.20 × 10−2 2.52
Chemoki e (C-X-C Motif)
ligand 8 CXCL8 1.49 × 10
−1 1.54 2.84 × 10−2 1.94
cytochro e c oxidase
subunit VIIb COX7B 4.23 × 10
−1 1.17 5.53 × 10−3 1.76
matrix etallopeptidase 16
(membrane-inserted) MMP16 8.78 × 10
−1 −1.04 2.34 × 10−2 1.73
fatty acid binding protein 4 FABP4 2.92 × 10−2 1.58 2.53 × 10−2 1.60
lymphocyte antigen 96 LY96 2.29 × 10−1 1.18 2.01 × 10−3 1.57
tissue factor pathway
inhibitor 2 TFPI2 6.17 × 10
−1 1.06 2.07 × 10−4 1.55
HUVEC were incubated with high glucose concentration 16.5 mmol/L and 0.01 mmol/L metformin then chemical
hypoxia was induced by 150 µmol/L C Cl2. Affymetrix .CEL files were imported to Partek Geno ic Suite
version 6.6 and normalized using RMA. Differentially expressed gene sets were generated using one-way ANOVA,
FDR-unadjusted p-value < 0.05 and fold change (FC) cutoff of 1.5 compared pairwise, i.e., the condition treated with
and without metformin. Subsequently, the most influenced genes were compared among different conditions of
hypoxia. The signs in the FC column denote (−) downregulated, (+) upregulated genes.
2.8. Inhibiti n of Metformin Action Mediated by MMP16 in Cell Migration Assay
To confirm that MMP16 mediates the effect of metformin on cell migration, we used an MMP16
antagonist, marimastat. Treatment with marimastat reversed the positive effect of metformin on cell
migration at 18h (p < 0.01) and 24 h (p < 0.001) as shown in Figure 7A,C. As metformin had no effect on
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VEGF signaling in HUVEC exposed to euglycemia-CoCl2, marimastat had no effect on cell migration
of ECs treated with metformin under euglycemia-CoCl2 versus parallel conditions without metformin
(Figure 7B).Int. J. Mol. Sci. 2018, 19, 293 9 of 18 
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hyperglycemia-CoCl2. (A) HUVEC were incubated with euglycemia or hyperglycemia in the presence
or absence of metformin for 24 h. Images were acquired every hour, and three independent biological
experiments were performed in duplicate for each condition. The scratch area was measured using
NIS Elements software. (B) Marimastat had no significant effect on cells treated with euglycemia,
metformin and CoCl2 induction. (C) The effect of metformin was inhibited by marimastat treatment.
Results are expressed as mean ± SEM and were analyzed using one-way ANOVA followed by LSD,
†† p < 0.01, ††† p < 0.001 compared with mari astat treated versus untreated-condition. Scale bar is 100
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3. Discussion
Large randomized controlled trial has shown that metformin improves CVD outcome in diabetic
patients [6]. The current study was aimed to understand the echanism behind the action of metformin,
in order to facilitate the identification of novel markers and therapeutic targets to reduce macrovascular
disease. Therefore, we report the effect of metformin on cell survival and migration under conditions
of acute hyperglycemia and hyperglycemia-chemical hypoxia combined, with the focus on important
VEGF pathway targets. Furthermore, to keep our research relevant to clinical practice, we specifically
avoided supra-physiological doses of metformin and used concentrations as anticipated in patients
treated with metformin [12]. In addition, we have used relevant hyperglycemia (16.5 mmol/L) which
can be observed in diabetic patients as opposed to extremely high glucose levels that are taken up by
numerous studies [14,15]. This glucose concentration was also high enough to cause inflammatory
changes without causing cytotoxicity [16,17].
Impaired angiogenesis in response to ischemia is elaborated as major macrovascular complications
in DM [18]. Additionally, previous study on streptozotocin-induced diabetic mice showed impaired
cell migration and tube formation which was improved by metformin [19]. This enhanced effect was
attributed to i creased expression of phosphorylated-AMP-activated protein ki ase, phosph rylated-
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endothelial nitric oxide synthase and augmented nitric oxide production by metformin in endothelial
cells of diabetic mice. For the first time, we have shown that physiological concentrations of
metformin improved EC survival and migration under hyperglycemia-chemical hypoxia through
activation of VEGF signaling pathway. In our study, an exposure of EC to hyperglycemia lead to
a marked increase in cell migration when compared to euglycemia and reduction in cell migration
when treated with hyperglycemia-CoCl2, as reported previously [20]. Furthermore, we have shown
that metformin inhibited cell migration under euglycemia-CoCl2 while improving migration under
hyperglycemia-CoCl2. Esfahanian et al., have reported a similar inhibiting effect of metformin
in EC migration under euglycemia although at supra-physiological metformin (0.5–3.0 mmol/L)
concentrations [21].
Vascular remodeling by cell migration and angiogenesis is regulated mainly by VEGF
signaling [22]. It has been established by others that VEGFA production is regulated by HIF which
supports an early involvement of VEGF in angiogenesis [23]. As a downstream of HIF, VEGF induction
by hypoxia is delayed with maximal levels at 48 h as reported by others [24,25]. Metformin’s effect
on VEGFA165 protein is short lived under hyperglycemia-CoCl2 (1 h), and this may be beneficial
as a protective mechanism against prolonged angiogenesis. For instance, 1 h of chemical hypoxia
is a critical time defined in clinical practice when patients benefit from cardiovascular intervention
following acute myocardial infarction.
Our microarray experiments demonstrated that metformin upregulated downstream targets in
VEGFA pathway; MMP16, FABP4, ROCK1, TFPI2, CXCL-8, and LY96 under hyperglycemia-CoCl2,
which play a part in cell migration. The role of metformin on migration was confirmed in our
experiments using VEGF and MMPs inhibitors. MMP16 is a membrane-type MT3-MMP that
contributes to angiogenesis by degrading extracellular matrix components, thus promoting cell
migration and bioavailability of growth factors [26,27]. Park et al., showed that upon secretion, VEGF
becomes bound to the extracellular matrix (ECM) and acts in a paracrine fashion [28]. The interaction
of VEGF with matrix proteins is mediated through the carboxy-terminal region, also known as an
ECM-binding domain [29,30]. The regulation of VEGF in the extracellular environment has also been
implicated in the angiogenic switch [31]. A prior study found that inhibition of MMP16 significantly
reduces the VEGFA-enhanced tube formation in ECs [32]. This is in agreement with our results from
the scratch assay where the pro-angiogenic effect of metformin in the combined hyperglycemia-CoCl2
treatment was inhibited by marimastat, an MMP inhibitor.
A downstream mediator of VEGF/VEGFR2 in our study, FABP4 [33] was found to be increased
by metformin under hyperglycemia-CoCl2 at 12 h of CoCl2 enhancing cell survival and migration.
FABP4 knockdown in HUVEC has been shown to decrease cell migration and increase apoptosis [33],
whilst VEGF knockdown was lethal [34,35]. Additionally, metformin enhanced the expression of
ROCK1 under hyperglycemia-CoCl2, another moderator of cell migration. RhoA/ROCK signaling had
previously shown to promote endothelial migration in response to VEGFA through the modulation
of the actin cytoskeleton organization [36]. Moreover, ROCK activation appears to be a key event
in the initiation of angiogenic process by mediating an increase in endothelial permeability and
migration, whilst ROCK1 inhibitor suppressed cell migration as shown recently [37]. We also found
that metformin upregulated the proinflammatory chemokine CXCL8. This chemokine revealed
pro-angiogenic properties by preserving VEGFA expression and secretion [38], whereas anti-CXCL8
was reported to reduce EC migration [39].
A Kunitz-type serine proteinase inhibitor TFPI-2 [40], upregulated by metformin in our study,
was shown to be overexpressed in migrating EC [41]. Previous studies have demonstrated that VEGF
mediates the induction of TFPI-2 through ERK1/2 activation [42,43]. However, as TFPI-2 was detected
to control cell migration [41], it presumably acts as an important regulator to prevent excessive and
uncontrolled cell migration.
Our results demonstrate that metformin inhibited apoptosis under combined hyperglycemia-CoCl2
through VEGF and activation of VEGF downstream signaling pathways. This was confirmed by using
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VEGF inhibitor (sunitinib) in the apoptosis assay. It is known that VEGF activates the phosphorylation
of ERK1/ERK2 leading to activation of MAPK pathway, which is an essential step in determining
the survival of EC [44]. We found that the activity of the ERK/MAPK pathway was inhibited
by euglycemia-CoCl2, hyperglycemia, and hyperglycemia combined with CoCl2 at 12 h which is
measured by MAPK activation dual detection assay. A previous study demonstrated that the level of
phospho-ERK1/2 in astrocytes was elevated after 1 h ischemia and reached a maximal level after 4 h
ischemia, before decreasing at 5 h resulting in enhanced ischemia-induced cell death [45]. In another
study activation of ERK/MAPK signaling was required for cardioprotection from ischemia-reperfusion
injury in vivo through antagonism of apoptotic regulatory pathways [46]. In our experiments we
were able to demonstrate that metformin activates ERK/MAPK signaling in HUVEC exposed to
hyperglycemia-CoCl2, augmenting cell survival. Therefore, metformin may have properties to enhance
cardioprotection from ischemia-reperfusion; however, we have not studied the reperfusion phase in
our study.
Previous studies have shown that VEGFA expression was significantly elevated in diabetic
patients with chronic coronary heart disease, and the cellular response to VEGFA was attenuated
due to defect in VEGF receptors and downstream signal transduction [47,48]. Our data confirm
these findings of overexpression of VEGFA combined with downregulation of VEGFR2 and VEGF
downstream intracellular signaling in HUVEC exposed to hyperglycemia-CoCl2.
Thus, the pivotal effect of metformin as documented by us was to restore the VEGFA pathway
to non-diabetic state by augmenting the expression of VEGFR1 and VEGFR2 that transduce the
vasoprotective downstream signalings of VEGF (Figure 8); a mechanism also documented in other
cardioprotective therapies such as statins (HMG CoA reductase inhibitors) [49]. The lack of metformin’s
beneficial effect in euglycemia is related to the fact that the VEGF related genes were principally
unaltered in euglycemia-CoCl2. In line with these findings, clinical studies confirm that metformin
offers no benefit in cardiovascular outcome in non-diabetic individuals [50,51]. Our data shows that
metformin has a direct effect on several targets within VEGFA pathway and therefore could lead to
further drug discovery of other cardioprotective therapies.
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The activity of ERK1/2 was assessed by MAPK activation dual detection assay flow cytometry. The 
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4. Materials and Methods 
4.1. HUVEC Cultures 
The study was approved by the Biomedical Ethics Unit, Faculty of Medicine, King Abdulaziz 
University (approval number: 440-10) and NRES Committee North East-Sunderland, UK (approval 
number: 12/NE/0044). HUVEC were harvested from three independent umbilical cords as previously 
described [17]. All experiments were performed in passage two. HUVEC were incubated in a culture 
Figure 8. Comprehensive VEGF signaling network of genes and proteins involved in cell migration
and survival. Metformin-treated condition is compared to metformin-untreated condition under
hyperglycemia-CoCl2 for 12 h. The network was created by IPA software rendering VEGF signal
transduction pathways. The genes from microarray expression study that are represented with red
shades are upregulated, and green shades are downregulated, MMP16 was validated by qRT-PCR.
The activity of ERK1/2 was assessed by MAPK activation dual detection assay flow cytometry. The red
shade on functional assays denoted activation while green shade inhibition. Solid lines denoted direct
interaction; interrupted lines denoted indirect interaction.
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4. Materials and Methods
4.1. HUVEC Cultures
The study was approved by the Biomedical Ethics Unit, Faculty of Medicine, King Abdulaziz
University (approval number: 440-10) and NRES Committee North East-Sunderland, UK (approval
number: 12/NE/0044). HUVEC were harvested from three independent umbilical cords as previously
described [17]. All experiments were performed in passage two. HUVEC were incubated in a culture
medium with 5.5 mmol/L (euglycemia) or 16.5 mmol/L (hyperglycemia) glucose concentrations
(Sigma-Aldrich, Dorset, UK) for 24 h except for functional assays (scratch, apoptosis, MAPK) for
48 h [16,17] and in presence/absence of 0.01 mmol/L metformin (Sigma-Aldrich) for up to 24 h
or 48 h. Subsequently, HUVEC were incubated under normoxia or CoCl2 for 1, 3, or 12 h using
a final concentration of 150 µmol/L CoCl2 (Sigma-Aldrich, Dorset, UK) as per protocol [52] in the
same experiment. Whereas up to 24 h CoCl2 exposure was utilized in functional assays (scratch
assay, apoptosis). Metformin concentration was selected according to the peak plasma concentration
suggested by FDA fact sheet [10]. The concentration of metformin used was validated previously as
tube formation was increased at 0.005–0.05 mmol/L but decreased at 0.5 mmol/L [53].
4.2. In Vitro Scratch Assay (Cell Migration Assay)
HUVEC were subcultured onto 24 well plate (1 × 105 cells/well). Cells were incubated under
euglycemia or hyperglycemia in the presence/absence of metformin for 24 h. Scratch lines were
created on confluent HUVEC monolayers using 1000 µL pipette tip. The medium was replaced with
fresh medium containing respective concentrations of glucose and metformin, and then the cells
were exposed to CoCl2 for up to 24 h. As a negative control for cell migration, HUVEC were treated
with marimastat, an matrix metalloproteinase (MMP) inhibitor (Sigma-Aldrich, Dorset, UK) to a
final concentration of 10 µmol/L in DMSO [54] or 0.1 µmol/L sunitinib malate a VEGF inhibitor
(Sigma-Aldrich, Dorset, UK) [55]. A subtoxic sunitinib dose was selected based on our previously
published results [12]. Subsequently, the cells were incubated in a 5% CO2 chamber (OkoLab) for
24 h that was connected to the camera (Hamamatsu Orca ER, Hamamatsu, Japan). Cell migration
was examined by phase-contrast microscopy (Nikon Eclipse Tie, Tokyo, Japan) using software-based
autofocus (NIS Elements V4.13, Nikon, Tokyo, Japan). Images were acquired every hour, and three
independent biological experiments were performed at which each condition was assessed in duplicate.
The scratch area in each image was measured using NIS Elements software. Cell migration is presented
as a percentage of gap closure and has been calculated by the following equation:
The percentage o f gap closure =
Area (0)− Area (t)
Area (0)
× 100
where Area (0) is the area of scratch pre-migration, Area (t) is an area of the scratch after migration at
time t.
4.3. Apoptosis Assay
HUVEC were treated in passage two at 60% confluency. The supra-physiological concentration
of metformin 1.0 mmol/L on apoptosis was additionally used. Culture media and metformin were
replaced every 12 h. A positive control for the apoptosis assay was established by treating the cells
with 14 µmol/L sunitinib malate for 24 h. To measure apoptosis, Annexin V APC staining assay
(BD, Bioscience, San Jose, CA, USA) was performed according to the manufacturer’s recommendations
and acquiring 10,000 events by FACSAria III flow cytometer (BD, Bioscience, San Jose, CA, USA).
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4.4. Total RNA Extraction
Total RNA from HUVEC was extracted using the RNeasy Mini Kit (QIAGEN, Hilden, Germany)
and on-column DNase digestion with RNase-Free DNase set (QIAGEN) was performed according to
the manufacturer’s instructions. The integrity of RNA samples was assessed by using Agilent 2100
Bioanalyzer (Santa Clara, CA, USA) yielding high RNA Integrity Numbers (RIN) between 9.1 and 10.
4.5. Microarray Experiments and Gene Expression Analysis
Microarray experiments were performed using Affymetrix (Santa Clara, CA, USA) Human
Gene 1.0 ST arrays according to manufacturer’s instructions with minor modifications [17,56].
Three biological replicates were hybridized for each experimental condition resulting in a total of
48 microarray experiments.
Affymetrix CEL files were imported into Partek Genomic Suite version 6.6 (Partek Inc.,
Chesterfield, MO, USA) and then data were normalized and analyzed as described previously [12].
The complete dataset and associated experimental information were submitted to NCBI’s Gene
Expression Omnibus with accession number GSE46263. Ingenuity pathway analysis (IPA) software
version 9 (Ingenuity, Redwood City, CA, USA) was used to explore the Canonical Pathways that may
be activated or inhibited. Additionally, IPA assisted in detecting the interactive molecular and cellular
functions in each condition.
4.6. Quantitative RT-PCR
Total RNA (100 ng) from each sample was reversed transcribed to cDNA using SuperScript®
VILO™ cDNA Synthesis Kit (Life Technologies, Paisley, UK) in a final volume of 20 µL. cDNA were
quantified by hydrolysis probe real-time PCR performed with TaqMan® Universal Master Mix II
(Life Technologies) using StepOne Plus Real-time PCR system (Life Technologies) according to the
manufacturer’s recommendations. Expression of the selected genes VEGFA and MMP16 was validated
using TaqMan gene expression assays (VEGFA ID Hs0090005_m1, MMP16 ID Hs0023467_m1, Life
Technologies). Three independent biological replicates were tested for each gene, and all samples were
run in triplicates. The Comparative Ct (∆∆Ct) method was applied to the mean value of each triplicate
to quantify expression of the target genes, which were normalized to reference control gene for the
large ribosomal protein P0 [17] (Life Technologies).
4.7. Protein Studies
Protein was extracted using the mirVana PARIS (Ambion, Grand Island, NY, USA) and the
concentration was measured using Pierce Microplate BCA protein assay (Thermo Scientific, Waltham,
MA, USA) according to the manufacturer’s protocol. The concentration was scanned using ELISA plate
reader (Multiskan Ascent, Thermo Labsystems, Waltham, MA, USA). Western blots were performed
using commercially available kits (Life Technologies) XCell SureLock (Life Technologies) for protein
fractionation, and Mini Protean II (BioRad, Hercules, CA, USA) for blot transfer. Nitrocellulose
membranes (Life Technologies) were blocked with blocking buffer from Li-COR (Lincoln, NE, USA)
and blocking buffer was diluted 1:2 with 1× TBS-T for incubation with antibodies. Transferred
protein were probed for hypoxia-inducible factor-1α (HIF-1α, mouse monoclonal anti-HIF-1α, 5:3000;
Abcam, Cambridge, UK), VEGFA (mouse monoclonal anti-VEGFA, 1:1000; Abcam), and VEGF165A
(mouse monoclonal anti-VEGF 165A, 1:1000; Abcam) and subsequently a secondary antibody (IRDye®
680RD goat (polyclonal) anti-mouse IgG, 0.5:5000; Li-COR) was applied. β-actin (mouse monoclonal
anti-beta actin, 1:3000; Abcam) was used as a loading control. Anti-VEGF showed many extra protein
non-specific bands; therefore, we studied VEGF165A in detail. Bands were detected by infrared imager
Odyssey (Li-COR) and quantified by Image Studio Lite version 3.1 (Li-COR Biosciences, Lincoln, NE,
USA). For stripping, bound antibodies were removed by incubation in RestoreTM Plus Western Blot
Stripping Buffer (Thermo Scientific, Waltham, MA, USA).
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VEGFR1/Flt-1 (R & D Systems, Minneapolis, MN, USA), VEGFR-2 and phospho-VEGFR-2 (Cell
Signaling, Danvers, MA, USA) were assessed by ELISA according to the manufacturers’ instructions.
4.8. MAPK Activation Dual Detection Assay
The activation of mitogen-activated protein kinase (MAPK) signaling pathway was measured
by phosphorylation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) using the
FlowCellect™ MAPK Activation Dual Detection kit (Millipore, Darmstadt, Germany) which includes
two antibodies, a phospho-specific anti-phospho-ERK1/2 (Thr202/Tyr204, Thr185/Tyr187)-PE
and, for quantification of total levels of ERK, an anti-ERK1/2-Alexa Fluor® 647 conjugated
antibody. HUVEC were treated with 5.5 mmol/L) or 16.5 mmol/L glucose concentrations in the
presence/absence of metformin (0.01 mmol/L) for 48 h and then were exposed to CoCl2 for 12 h. All
conditions were assayed in 2 or 3 independent replicates. Culture media and metformin were replaced
every 12 h. For VEGF inhibitor assays, cells were incubated with EBM-2 medium containing VEGF as
a positive control or with EBM-2 medium containing 7 µmol/L sunitinib malate as a negative control.
Subsequently, 2 × 105 cells were fixed by an equal volume of ice-cold fixation buffer for 20 min and
processed according to the manufacturer’s instructions by acquiring 14,000 events using FACSAria III
flow cytometer.
4.9. Statistical Analysis
Results are presented as mean ± SEM. Statistical analysis was performed using one-way ANOVA
followed by post-hoc analysis Fisher’s least significant difference (LSD) test for qRT-PCR, ELISA,
western blot, and in vitro scratch assays. The Student’s t-test between any two experimental groups was
applied for the MAPK activation dual detection assay and Annexin V Apoptosis assay. Calculations
were performed using IBM SPSS software version 21.0 (SPSS Inc., Armonk, NY, USA). A p-value < 0.05
was considered statistically significant.
5. Conclusions
In conclusion, our in vitro study demonstrates that the effect of metformin in acute
hyperglycemia-chemical hypoxia model is mediated through restoring VEGFA pathway. This occurs
through upregulation of VEGFR1 and VEGFR2, leading to dual effect on activation of cell migration
through MMP16 and ROCK1 upregulation, in addition to inhibition of apoptosis by increase in
phospho-ERK1/2 and FABP4, components of VEGF signaling cascades.
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Abbreviations
CVD Cardiovascular disease
CXCL8 Chemokine (C-X-C Motif) Ligand 8
DM Diabetes mellitus
EC Endothelial cell
ERK1/2 Extracellular signal-regulated protein kinases 1 and 2
FABP4 Fatty acid binding protein 4
LY96 Lymphocyte antigen 96
MAPK Mitogen-activated protein kinase
MI Myocardial infarction
MMP16 Matrix metalloproteinase 16
PI3K Phosphatidylinositol 3′-kinase
ROCK1 Rho-associated, coiled-coil containing protein kinase 1
TFPI2 Tissue factor pathway inhibitor 2
VEGFA Vascular endothelial growth factor A
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